Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019

With the rapid development of research on coronavirus disease 2019(COVID-19),more and more attention has been drawn to its damage to extrapulmonary organs.There are increasing lines of evidence showing that liver injury is closely related to the severity of COVID-19,which may have an adverse impact on the progression and prognosis of the patients.What is more,severe acute respiratory syndrome coronavirus-2 infection,cytokine storm,ischemia/hypoxia reperfusion injury,aggravation of the primary liver disease and drug-induced liver injury may all contribute to the hepatic damage in COVID-19 patients;although,the drug-induced liver injury,especially idiosyncratic drug-induced liver injury,requires further causality confirmation by the updated Roussel Uclaf Causality Assessment Method published in 2016.Up to now,there is no specific regimen for COVID-19,and COVID-19-related liver injury is mainly controlled by symptomatic and supportive treatment.Here,we review the clinical features of abnormal liver enzymes in COVID-19 and pathogenesis of COVID-19-related liver injury based on the current evidence,which may provide help for clinicians and researchers in exploring the pathogenesis and developing treatment strategies.